New Drug Delays Type 1 Diabetes Onset

Teplizumab-mzwv, a monoclonal antibody that delayed the onset of clinically diagnosed stage 3 type 1 diabetes by a median of about 2 years in clinical trials, gained FDA approval for patients aged 8 years or older with stage 2 disease.